Gerard Abidor
Internal Medicine · Trumbull, CTNPI 1518014539
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,375, 2.1 times the $645 reported in 2019. Among internal medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$886
- AbbVie$676
- Novo Nordisk$670
- Abbott$370
- Lilly USA, LLC$220
- plus $1K from 19 others
What the payments were for
- Food & beverage$5,033100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 59 | $1,143 |
| AstraZeneca | 33 | $886 |
| AbbVie | 31 | $676 |
| Novo Nordisk | 32 | $670 |
| Abbott | 5 | $370 |
| Lilly USA, LLC | 7 | $220 |
| Axsome Therapeutics, Inc. | 4 | $174 |
| Merck | 9 | $149 |
| Sunovion Pharmaceuticals Inc. | 10 | $114 |
| Ardelyx, Inc. | 5 | $96 |
| Amgen | 5 | $94 |
| Pfizer | 3 | $67 |
| Exact Sciences | 3 | $61 |
| Phathom Pharmaceuticals, Inc. | 3 | $49 |
| Lundbeck LLC | 3 | $49 |
| Boehringer Ingelheim | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Viiv Healthcare Company | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Gilead | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,038 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 24 | $31,248 |
| JanuviaSitagliptin Phosphate | 16 | $14,608 |
| TradjentaLinagliptin | 13 | $12,617 |
| OzempicSemaglutide | 11 | $10,349 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,272 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,920 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $4,795 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,837 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,248 |
| Ventolin HfaAlbuterol Sulfate | 32 | $1,867 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,389 |
| Levothyroxine Sodium | 23 | $1,126 |
| Triamcinolone Acetonide | 21 | $885 |
| Amlodipine Besylate | 132 | $625 |
| Ammonium Lactate | 23 | $589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $886 | $34,08436 claims |
| MerckJanuvia | $149 | $14,60816 claims |
| Boehringer IngelheimTradjenta | $37 | $12,61713 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,143 | $12,19223 claims |
| Novo NordiskOzempic | $670 | $10,34911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Trumbull
- Amit MahajanTrumbull$36K
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$1.6M
- Arthur DecillisMadison$1M
- Charles MontanoCromwell$970K
- Gary BlickNorwalk$683K
- Scott GottliebStamford$508K
- Jeffrey KatzOxford$361K
- Nicholas DainiakBridgeport$352K
- Thomas PellechiGreenwich$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.